TY - JOUR TI - Autologous hematopoietic stem cell transplantation with inadequate stem cell dose in patients with non-Hodgkin lymphoma AU - Liu, Weiping AU - Wu, Meng AU - Xie, Yan AU - Zhang, Chen AU - Ping, Lingyan AU - Feng, Feier AU - Leng, Xin AU - Mi, Lan AU - Wang, Xiaopei AU - Zhu, Jun AU - Song, Yuqin T2 - Leukemia & Lymphoma AB - Little is known regarding the outcome of lymphoma patients undergoing autologous hematopoietic stem cell transplantation (AHSCT) using inadequate hematopoietic stem cell (HSC) doses. Fifty-six patients were enrolled in the study, and the cohort was subdivided into two groups according to the infusion dose: < 1 × 106/kg (poor HSC group) and 1–2 × 106/kg (unfavorable HSC group). Compared with the unfavorable group, the poor HSC group had a longer median time to neutrophil (13 vs. 11 days, p = .007) and platelet engraftment (17 vs. 13 days, p = .024). CD34+ cell infusion dose of < 1 × 106/kg was the only risk factor for neutrophil and platelet engraftment. The expected 3-year progression-free survival and overall survival rates for the whole cohort were 53% and 66%, and no statistical difference was observed between two groups. In conclusion, inadequate HSC infusion dose did not negatively impact AHSCT patient survival but significantly prolonged the time to hematopoietic engraftment. DA - 2020/10/15/ PY - 2020 DO - 10.1080/10428194.2020.1834092 DP - Taylor and Francis+NEJM VL - 0 IS - 0 SP - 1 EP - 7 SN - 1042-8194 UR - https://doi.org/10.1080/10428194.2020.1834092 Y2 - 2020/10/20/19:13:50 KW - Hematopoietic stem cell transplantation KW - Non-Hodgkin’s KW - lymphoma KW - safety KW - survival ER -